Laekna (HKEX: 02105) has licensed its pre-clinical PI3Kα inhibitor LAE118 to US-based Vasque Bio in a deal worth up to USD 527 million. Vasque will serve as a rare-disease-focused channel for the global development of Laekna's next-generation mutant-selective kinase inhibitor, which has cleared IND review in both the US and China. The LAE118 license agreement, announced on June 9, 2026, grants Vasque Bio exclusive worldwide rights excluding Greater China to develop, manufacture, and commercialize the compound. The deal's equity component — Laekna's right to acquire up to a high-teen percentage of Vasque Bio stock at no additional cost — gives the originator direct exposure to any future exit.
Under the terms, Laekna receives a USD 10 million non-refundable upfront payment, up to USD 517 million in combined development and sales milestones, and tiered royalties ranging from single-digit to double-digit percentages on any future net sales. A further clause entitles Laekna to up to 50% of the value of any qualifying strategic transaction — such as an acquisition or sublicense — that Vasque Bio enters involving LAE118. That provision is structurally uncommon and suggests Laekna negotiated aggressively to guard against a scenario where Vasque Bio exits cheaply before milestones are earned.
Laekna's PI3Kα inhibitor
LAE118 is described by Laekna as a novel PI3Kα pan-mutant selective inhibitor, designed to target the mutant forms of the PI3Kα enzyme while sparing the wild-type protein. First-generation PI3Kα inhibitors, including Novartis's alpelisib (Piqray/Vijoice), inhibit both mutant and wild-type enzyme, producing on-target toxicities — particularly hyperglycemia — that limit dosing and combination potential. Mutant-selective agents aim to widen the therapeutic window by concentrating activity on disease-driving variants. According to Laekna, LAE118 is being actively developed into clinical studies for PIK3CA-mutant solid tumors in both China and the US.
The partnership introduces an unusual indication split. Laekna describes its own development focus as oncology, while Vasque Bio — backed by The Column Group and F-Prime — is described as a company dedicated to rare diseases. PIK3CA gain-of-function mutations drive not only common cancers but also a spectrum of rare overgrowth conditions known as PIK3CA-related overgrowth spectrum disorders, where targeted PI3Kα inhibition has shown biological rationale.
Industry and transaction context
The LAE118 license agreement arrives in the middle of a concentrated wave of large-pharma and venture capital activity targeting next-generation PI3Kα mutant-selective inhibitors. In March 2026, Novartis agreed to acquire Synnovation Therapeutics' pan-mutant selective PI3Kα program SNV4818 for up to USD 3 billion, paying USD 2 billion upfront — a transaction that set a high-water mark for the class.